Search

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Starting this November: EHA Guidelines Workshops!

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.

Read more

SWG Education Activities

Session at EHA2023The EHA2023 Congress was held in Frankfurt in June 2023. During the event, we held a session with the EHA Adolescent and Young Adult (AYA) Taskforce on the treatment of AYA patients with acute lymphoblastic leukaemia (ALL).

Read more

Meetings Sponsor Program

The European Hematology Association (EHA) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. We bring together relevant stakeholders to promote excellence in patient care through education, research, and advocacy.

Read more

Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group

Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.

Read more

Guidelines Committee

Current committee members
Noémi Roy, United Kingdom (Chair)
Martin Dreyling, Germany (Vice-Chair)
Steffen Koschmieder, Germany (Executive member)
Marieke Kruip, The Netherlands (Executive member)
Area associate members
Tamam Bakchoul, Germany
Sabine Blum, Switzerland 
Cristina Castilla Llorente, France 
Lydie Da Costa, France
Wojciech Jurczak, Poland
Giovanna Russo, Italy
Cynthia So-Osman, The Netherlands
AimThe aim of…

Read more